Table 2.

Univariate analysis on relapse probability.

Variable	Value	Relapse			Relapse free survival
		No	Yes	p	HR (95% CI)	p
AR (%)		80 (60−90)	70 (12.5−80)	0.011	0.99 (0.99−1)	0.025
	<80%	52 (53.06%)	46 (46.94%)	0.002	Baseline
	⩾80%	81 (73.64%)	29 (26.36%)		0.53 (0.34−0.85)	0.008
ER (%)		80 (70−80)	70 (60−80)	0.038	0.99 (0.98−1)	0.068
	<80%	54 (40.6%)	41 (54.67%)	0.060	Baseline
	⩾80%	79 (59.4%)	34 (45.33%)		0.69 (0.44−1.09)	0.116
AR/ER ratio		1 (0.8−1.12)	0.89 (0.29−1.12)	0.281	1.06 (0.88−1.27)	0.536
	<2	125 (64.77%)	68 (35.23%)	0.410	Baseline
	⩾2	8 (53.33%)	7 (47.67%)		1.47 (0.67−3.20)	0.334
Grade	G1 − G2	97 (65.54%)	51 (34.46%)	0.524	Baseline
	G3	36 (60%)	24 (40%)		1.24 (0.76−2.01)	0.394
Stage	I	76 (81.72%)	17 (18.28%)	1	Baseline
	yI	6 (85.71%)	1 (14.29%)		0.89 (0.12−6.77)	0.912
	II	32 (55.17%)	26 (44.83%)	1	Baseline
	yII	8 (53.33%)	7 (46.67%)		0.79 (0.34−1.83)	0.581
	III	10 (50%)	10 (50%)	0.022	Baseline
	yIII	1 (7.69%)	12 (92.31%)		1.46 (0.6−3.52)	0.405
Vascular invasion	Absent	64 (77.11%)	19 (22.89%)	0.061	Baseline
	Mild	42 (61.76%)	26 (38.24%)		1.80 (1−3.26)	0.051
	Diffuse	7 (53.85%)	6 (46.15%)		2.23 (0.89−5.6)	0.086
Histotype	NOS/ductal	87 (66.41%)	44 (33.59%)	0.485	Baseline
	Lobular	39 (58.21%)	28 (41.79%)		1.13 (0.7−1.81)	0.620
	Other	7 (70.00%)	3 (30.00%)		0.89 (0.28−2.88)	0.850
ki67	<20%	103 (69.59%)	45 (30.41%)	0.011	Baseline
	⩾20%	30 (50%)	30 (50%)		2.3 (1.44−3.66)	<0.001

AR, androgen receptor; baseline, intercept of the regression; CI, 95% confidence interval; ER, estrogen receptor; HR, hazard ratio; NOS, not otherwise specified; p = unadjusted p-value from Wilcoxon rank sum test, Chi-square test, or Fisher’s exact test as appropriate; value, value that the variable assumes; variable, analyzed variable; yI – yII – yIII, patients who performed neoadjuvant treatment.